Physician profile
Jane Jesse
NPI 1508060112
$616,754.14
in general payments reported to CMS, 2019-2025
22 companies · $110K in 2025
The $110K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84K · 2020: $16K · 2021: $88K · 2022: $112K · 2023: $82K · 2024: $125K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $246K · Travel and Lodging: $31K · Consulting Fee: $30K · Food and Beverage: $9,295 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $245,592.00 |
| Travel and Lodging | $31,295.40 |
| Consulting Fee | $30,275.00 |
| Food and Beverage | $9,295.35 |
| Education | $198.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $573,850.03 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $33,914.81 | 2021-2024 | |
| Allergan, INC. | $5,598.55 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $557.50 | 2019-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $440.32 | 2019-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $436.44 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $392.91 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.39 | 2020-2025 | Caplyta |
| Alkermes, INC. | $264.57 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $192.60 | 2019-2021 | |
| Lundbeck LLC | $172.53 | 2019-2024 | Rexulti |
| Indivior INC. | $138.43 | 2019-2025 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $115.53 | 2023-2024 | Auvelity |
| Shire North American Group INC | $112.44 | 2019 | |
| Neurocrine Biosciences, INC. | $67.32 | 2019-2025 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $32.91 | 2024 | Qelbree |
| Neuronetics, INC. | $32.02 | 2019 | |
| Ironshore Pharmaceuticals INC. | $25.97 | 2019 | |
| Neos Therapeutics, Lp | $25.52 | 2022 | |
| Bausch Health US, LLC | $16.97 | 2025 | Aplenzin |
| Braeburn INC. | $14.76 | 2025 | Brixadi |
| Aytu Biopharma, INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Jesse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.